FGFR4

Overview

One-paragraph summary of the gene’s role and why it matters in cancer genomics.

Alterations observed in the corpus

  • Mutation classes (missense / truncating / fusion / amplification / deletion) with links to the papers that report them.
  • 3 kinase domain mutations in 188 LUAD tumours; co-occurrence with NTRK2 and PDGFRA mutations noted. PMID:18948947
  • Mutated in breast cancer (TCGA, 510 tumors); somatic mutations identified across subtypes PMID:23000897
  • Mutation identified in adenoid cystic carcinoma (ACC); receptor tyrosine kinase in the FGF signaling pathway PMID:23685749
  • FGFR4 recurrently mutated in 9.6% of fusion-negative rhabdomyosarcoma (PFN) tumors and 0% of fusion-positive (PFP) tumors; shared leading-edge PAX-FOXO1 downstream target; RAS/FGFR4 pathway mutationally activated in ≥45% of PFN tumors; MEK inhibition proposed as a therapeutic strategy PMID:24436047
  • FGFR4 is the predominant hepatic FGFR; a therapeutic target in HCC via selective inhibitors BLU-554, H3B-6527, and FGF401, enriched by FGF19 IHC positivity (≥1%). PMID:24798001
  • Present in the untreated primary (TURBT) of patient WCM117 but absent from post-chemotherapy metastases in urothelial carcinoma, private to the eradicated clone PMID:27749842
  • G528C, V550L, and R650L hotspot mutations detected in two pediatric patients with rhabdomyosarcoma (RMS) in the PIPseq cohort; classified as FGFR4-inhibitor targets PMID:28007021.

Cancer types (linked)

  • Per cancer type: prevalence, co-mutation patterns, clinical significance.

Co-occurrence and mutual exclusivity

  • Linked partner genes with the relationship and the paper(s) reporting it.

Therapeutic relevance

  • Drugs (linked) targeting this gene or its pathway, with the studies supporting them.

Open questions

  • Conflicts or unresolved findings across papers.

Sources

This page was processed by entity-page-writer on 2026-05-11. - PMID:18948947

This page was processed by entity-page-writer on 2026-05-11. - PMID:23000897

This page was processed by entity-page-writer on 2026-05-11. - PMID:23685749

This page was processed by entity-page-writer on 2026-05-11. - PMID:24436047

This page was processed by entity-page-writer on 2026-05-11. - PMID:24798001

This page was processed by entity-page-writer on 2026-05-11. - PMID:27749842

This page was processed by entity-page-writer on 2026-05-15. - PMID:28007021

This page was processed by wiki-cli on 2026-05-14.